---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-018718"
form_type: "8-K"
ticker: "MBOT"
cik: "0000883975"
company_name: "Microbot Medical Inc."
filed_at: "2023-05-23T23:59:59+00:00"
generated_at: "2026-06-14T17:43:27.116513+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Microbot Medical raises $1.4M in registered direct offering of common stock at $2.20/share

## Summary
- Sold 655,569 shares of common stock at $2.20/share for gross proceeds of ~$1.44M.
- Proceeds to fund LIBERTY Robotic System development, IP expansion, and working capital.
- H.C. Wainwright acted as exclusive placement agent; received 7.0% cash fee and 32,778 warrants at $2.75.
- Offering closed on May 23, 2023; shares issued under effective shelf registration statement.
- Company imposed 5-trading-day restriction on future equity sales after closing.

## SEC filing metadata
- accession: 0001493152-23-018718
- form_type: 8-K
- ticker: MBOT
- cik: 0000883975
- company_name: Microbot Medical Inc.
- filed_at: 2023-05-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/883975/000149315223018718/0001493152-23-018718-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/883975/000149315223018718/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-018718
- JSON: https://secwatch.observer/filing/0001493152-23-018718.json
- Plain text: https://secwatch.observer/filing/0001493152-23-018718.txt

## Key facts
- Material Agreements
  Microbot Medical Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC valued at an aggregate cash fee equal to 7.0% of the gross proceeds (effective 2023-05-16).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: H.C. Wainwright & Co., LLC
  - Value: an aggregate cash fee equal to 7.0% of the gross proceeds
  - Effective: 2023-05-16
  source text: On May 16, 2023 and in connection with the Offering, the Company entered into an engagement letter (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company pursuant to the Purchase Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/883975/000149315223018718/0001493152-23-018718-index.htm
- Material Agreements
  Microbot Medical Inc. entered into Securities Purchase Agreement with an institutional investor valued at aggregate gross proceeds from the Offering of approximately $1.4 million (effective 2023-05-22).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an institutional investor
  - Value: aggregate gross proceeds from the Offering of approximately $1.4 million
  - Effective: 2023-05-22
  source text: On May 22, 2023, Microbot Medical Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market (the “Offering”), an aggregate of 655,569 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), at an offering price of $2.20 per share, for aggregate gross proceeds from the Offering of approximately $1.4 million before deducting the placement agent fee (as described in greater detail below) and related offering expenses.
  evidence_url: https://www.sec.gov/Archives/edgar/data/883975/000149315223018718/0001493152-23-018718-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.